

TABLE OF CONTENTS

RATIFICATION PAGE.....	ii
PLAGIATION-FREE STATEMENT	iii
DEDICATION PAGE	iv
PREFACE	v
LIST OF FIGURES.....	viii
LIST OF TABLES.....	x
TABLE OF EQUATIONS.....	xi
ABSTRACT.....	xii
INTISARI.....	xiii
CHAPTER I	1
I.1 Background	1
I.2 Research Objectives	2
I.3 Research Benefits	2
CHAPTER II.....	4
II.1 Theoretical Background	4
II.1.1 Mangiferin.....	4
II.1.2 Homomangiferin	5
II.1.3 Isomangiferin	6
II.1.4 Neomangiferin.....	7
II.1.5 Mangiferin 6'-Gallate.....	8
II.1.6 Norathyriol	10
II.1.7 HCC	11
II.1.8 Wnt/ β -catenin pathway	12
II.1.9 Molecular Docking & Dynamics	13
II.2 Hypothesis Formulation & Research Design	15
III.2.1 Hypothesis Formulation 1	15
III.2.2 Hypothesis Formulation 2	15
III.2.3 Research Design.....	16
CHAPTER III	17

III.1	Materials	17
III.2	Equipment	17
III.3	Procedure	17
III.3.1	Obtaining the ligands and receptors' structures	17
III.3.2	Cleaning the ligand and receptors	18
III.3.3	Molecular docking	20
III.3.4	Molecular dynamics	20
III.3.4	MD analysis	21
CHAPTER IV		22
IV.1	Docking Results	22
IV.2	Docking Interaction Analysis	27
IV.3	Key Residue Analysis.....	31
IV.5	Homomangiferin-WT1 Molecular Dynamics Results.....	35
IV.6	Neomangiferin-WT1 Molecular Dynamics Results.....	41
CHAPTER V		46
V.1	Conclusion.....	46
V.2	Recommendation.....	46
REFERENCES		47
APPENDIX		52

LIST OF FIGURES

Figure II.1 Chemical structure of mangiferin	4
Figure II.2 Chemical structure of homomangiferin	5
Figure II.3 Chemical structure of isomangiferin.....	7
Figure II.4 Chemical structure of neomangiferin.....	8
Figure II.5 Chemical structure of mangiferin 6'-gallate	9
Figure II.6 Chemical structure of norathyriol	10
Figure II.7 Illustration of Wnt/ β -catenin biological pathway	12
Figure III.1 From top-left: WT1 (6B0O), LEF1 (3OUX), FZD7 (6NE2), and CTNNB1 (1JDH) protein structures (Berman et al., 2000)	19
Figure IV.1 3D diagram of protein-receptor interaction of A) Homomangiferin-WT1, B) Neomangiferin-WT1	26
Figure IV.2 2D diagram of ligand and target-receptor interaction between homomangiferin and WT1	27
Figure IV.3 2D diagram of ligand and target-receptor interaction between neomangiferin and WT1	29
Figure IV.4 Chemical structures of A) ASP (Aspartic acid), B) CYS (Cysteine), C) GLU (Glutamic acid), D) LYS (Lysine), and E) PHE (Phenylalanine)	32
Figure IV.5 Wilms' Tumor 1 N-terminal and zinc finger domain.....	34
Figure IV.6 Ligand movement RMSD after superposing on the receptor for homomangiferin-WT1.....	36
Figure IV.7 Ligand conformation RMSD after superposing on the ligand for homomangiferin-WT1.....	36
Figure IV.8 Solute protein/nucleic acid residue RMSF for homomangiferin WT1 (Mol A represents WT1, Mol D represents DNA)	38
Figure IV.9 Radius of gyration of the solute of homomangiferin-WT1	39
Figure IV.10 Number of hydrogen bonds made by homomangiferin and WT1 ...	40
Figure IV.11 Ligand movement RMSD after superposing on the ligand for neomangiferin-WT1	41

Figure IV.12 Ligand conformation RMSD after superposing on the ligand for neomangiferin-WT1	41
Figure IV.13 Solute protein/nucleic acid residue RMSF for neomangiferin-WT1	43
Figure IV.14 Radius of gyration of the solute for neomangiferin-WT1	44
Figure IV.15 Number of hydrogen bonds made by neomangiferin and WT1	45

LIST OF TABLES

Table IV.1 Mangiferin derivatives binding energy with Wnt/ β -catenin pathway receptors	22
Table V.1 Key residue interaction between homomangiferin and neomangiferin against WT1	52

TABLE OF EQUATIONS

Equation IV.1 Formula to calculate RMSD (Root Mean Square Deviation) and RMSF (Root Mean Square Fluctuation)	35
---	----